Oculis Holding AG, a clinical-stage biopharmaceutical company develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and globally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema.
Its portfolio also includes OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease, and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. Founded in 2017, the company is based in Zug, Switzerland.
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases. Its lead product candidate is OCS-01, a topical dexamethasone optireach formulation currently in Phase 3 clinical trials for diabetic macular edema. The company's portfolio also includes OCS-02, a topical biologic candidate in Phase 2b trials for dry eye disease, and OCS-05, a disease-modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis. Oculis operates in Switzerland and globally, aiming to address unmet medical needs in eye and neurological health.
On which stock exchange is Oculis Holding AG (OCS) listed and what currency does it trade in?
Oculis Holding AG is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol OCS. Its shares trade in US dollars (USD). The company is headquartered in Zug, Switzerland, but its listing on a US exchange provides access to American and international investors. The NasdaqGM is a tier of the Nasdaq stock exchange that lists companies meeting specific financial and liquidity requirements, making Oculis accessible to a broad range of traders and institutional investors.
What sector and industry does Oculis Holding AG (OCS) belong to?
Oculis Holding AG operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative drug candidates for ophthalmic and neurological conditions. Biotechnology companies like Oculis use biological processes and living organisms to create therapies, often targeting diseases with high unmet needs. The company's work in ophthalmology and neurology places it at the intersection of two specialized medical fields, leveraging drug delivery technologies such as its optireach formulation to improve treatment outcomes.
Where is Oculis Holding AG (OCS) headquartered and what markets does it serve?
Oculis Holding AG is headquartered in Zug, Switzerland, and operates globally, serving markets in Switzerland and internationally. The company was founded in 2017 and originally known as Oculis SA before changing its name to Oculis Holding AG in March 2023. While its primary operations are based in Switzerland, its clinical trials and potential future commercialization target patients worldwide, particularly those with ophthalmic and neurological diseases. The company's global reach is reflected in its pipeline, which addresses conditions prevalent across diverse populations, such as diabetic macular edema and dry eye disease.
What are the main product candidates in Oculis Holding AG's (OCS) pipeline?
Oculis Holding AG's pipeline includes three key product candidates. OCS-01 is a topical dexamethasone optireach formulation in Phase 3 trials for diabetic macular edema, a leading cause of vision loss. OCS-02 is a topical biologic candidate in Phase 2b trials for dry eye disease, a common condition affecting tear film stability. OCS-05 is a disease-modifying neuroprotective agent for neurological damage, with indications for glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis. These candidates leverage the company's optireach drug delivery technology, which aims to enhance ocular bioavailability and patient compliance.